Comorbidity of erosive gastroesophageal reflux disease and irritable bowel syndrome. Clinical case
DOI: https://dx.doi.org/10.18565/pharmateca.2025.4.48-53
Kozlova I.V., Tikhonova T.A.
Saratov State Medical University named after V.I. Razumovsky, Saratov, Russia
Background: Currently, significant importance is attached to comorbidity in gastrointestinal diseases. Comorbidity of gastroesophageal reflux disease and irritable bowel syndrome is associated with the presence of common pathophysiological mechanisms and is associated with a decrease in the quality of life.
Description of the clinical case: The article considers a clinical case of overlap syndrome of gastroesophageal reflux disease with erosive esophagitis and irritable bowel syndrome in a 37-year-old patient, as well as the effectiveness of therapy using a proton pump inhibitor and a selective myotropic antispasmodic in this case.
Conclusion: The combination of a PPI (pantoprazole) and a selective myotropic antispasmodic (mebeverine hydrochloride) can be considered when choosing therapy in comorbid patients.
About the Autors
Tatyana A. Tikhonova, Associate Professor, Department of Therapy, Gastroenterology and Pulmonology, Saratov State Medical University named after V.I. Razumovsky, Saratov, Russia; jdipisma@mail.ru, ORCID: https://orcid.org/0000-0002-0981-1083, Web of Science ResearcherID: AAA-9469-2021, Scopus Author ID: 57339702600, eLibrary SPIN: 4101-1360 (corresponding author)
Irina V. Kozlova, Saratov State Medical University named after V.I. Razumovsky, Saratov, Russia; ORCID: https://orcid.org/0000-0002-5056-4504, Web of Science ResearcherID: B-2802-2017, Scopus Author ID: 7102626490, eLibrary SPIN: 7995-5124
Similar Articles